- Home
- BKYI vs ENVB Comparison
BKYI vs ENVB Comparison
Compare BKYI & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKYI | ENVB |
|---|---|---|
| Founded | 1993 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 3.0M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | BKYI | ENVB |
|---|---|---|
| Price | $0.58 | $4.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 228.7K | ★ 2.1M |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,316,050.00 | N/A |
| Revenue This Year | $7.45 | N/A |
| Revenue Next Year | $23.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $3.50 |
| 52 Week High | $3.68 | $96.30 |
Technical Indicators
Market Signals| Indicator | BKYI | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 41.97 | 45.33 |
| Support Level | $0.58 | $3.50 |
| Resistance Level | $0.64 | $4.09 |
| Average True Range (ATR) | 0.04 | 0.35 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 38.92 | 33.50 |
Price Performance
Historical ComparisonAbout BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.